JP2021522798A5 - - Google Patents
Info
- Publication number
- JP2021522798A5 JP2021522798A5 JP2020561821A JP2020561821A JP2021522798A5 JP 2021522798 A5 JP2021522798 A5 JP 2021522798A5 JP 2020561821 A JP2020561821 A JP 2020561821A JP 2020561821 A JP2020561821 A JP 2020561821A JP 2021522798 A5 JP2021522798 A5 JP 2021522798A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- composition according
- express
- antigen
- hiv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024000389A JP2024045179A (ja) | 2018-05-03 | 2024-01-05 | 免疫チェックポイント遮断によりキメラ抗原受容体を発現するように操作されたナチュラルキラー細胞 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862666665P | 2018-05-03 | 2018-05-03 | |
| US62/666,665 | 2018-05-03 | ||
| US201862666965P | 2018-05-04 | 2018-05-04 | |
| US62/666,965 | 2018-05-04 | ||
| PCT/US2019/030721 WO2019213610A1 (en) | 2018-05-03 | 2019-05-03 | Natural killer cells engineered to express chimeric antigen receptors with immune checkpoint blockade |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024000389A Division JP2024045179A (ja) | 2018-05-03 | 2024-01-05 | 免疫チェックポイント遮断によりキメラ抗原受容体を発現するように操作されたナチュラルキラー細胞 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021522798A JP2021522798A (ja) | 2021-09-02 |
| JP2021522798A5 true JP2021522798A5 (enExample) | 2022-05-09 |
Family
ID=68386134
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020561821A Ceased JP2021522798A (ja) | 2018-05-03 | 2019-05-03 | 免疫チェックポイント遮断によりキメラ抗原受容体を発現するように操作されたナチュラルキラー細胞 |
| JP2024000389A Pending JP2024045179A (ja) | 2018-05-03 | 2024-01-05 | 免疫チェックポイント遮断によりキメラ抗原受容体を発現するように操作されたナチュラルキラー細胞 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024000389A Pending JP2024045179A (ja) | 2018-05-03 | 2024-01-05 | 免疫チェックポイント遮断によりキメラ抗原受容体を発現するように操作されたナチュラルキラー細胞 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210230548A1 (enExample) |
| EP (1) | EP3788061A4 (enExample) |
| JP (2) | JP2021522798A (enExample) |
| KR (1) | KR20210005240A (enExample) |
| CN (1) | CN112292390A (enExample) |
| AU (1) | AU2019262218B2 (enExample) |
| BR (1) | BR112020022010A2 (enExample) |
| CA (1) | CA3099342A1 (enExample) |
| CO (1) | CO2020015168A2 (enExample) |
| MX (1) | MX2020011697A (enExample) |
| NZ (1) | NZ770183A (enExample) |
| SG (1) | SG11202010763VA (enExample) |
| WO (1) | WO2019213610A1 (enExample) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104740624B (zh) | 2007-09-18 | 2018-04-24 | 武田疫苗股份有限公司 | 赋予针对诺如病毒的保护性免疫应答的疫苗 |
| EP4112074A1 (en) | 2011-07-11 | 2023-01-04 | Takeda Vaccines, Inc. | Parenteral norovirus vaccine formulations |
| EP3612210A4 (en) * | 2017-04-19 | 2021-01-27 | Board Of Regents, The University Of Texas System | MANIPULATED ANTIGEN RECEPTORS EXPRESSING IMMUNE CELLS |
| BR112020008568A2 (pt) | 2017-11-09 | 2020-10-06 | Sangamo Therapeutics, Inc. | modificação genética de gene de proteína contendo sh2 indutível por citoquina (cish) |
| IL276365B2 (en) | 2018-02-01 | 2023-10-01 | Nkmax Co Ltd | A method for the production of natural killer cells and a preparation for cancer treatment |
| US12473336B2 (en) | 2018-02-21 | 2025-11-18 | Board Of Regents, The University Of Texas System | Methods for activation and expansion of natural killer cells and uses thereof |
| US20210228630A1 (en) | 2018-05-16 | 2021-07-29 | Research Institute At Nationwide Children's Hospital | Generation of knock-out primary and expanded human nk cells using cas9 ribonucleoproteins |
| EP3773918A4 (en) | 2019-03-05 | 2022-01-05 | Nkarta, Inc. | CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY |
| MX2021011816A (es) * | 2019-03-29 | 2021-10-22 | Univ Texas | Metodos para produccion de celulas car-nk y uso de las mismas. |
| AU2020288829A1 (en) * | 2019-06-04 | 2021-12-02 | Nkarta, Inc. | Combinations of engineered natural killer cells and engineered T cells for immunotherapy |
| ES2973832T3 (es) | 2019-10-18 | 2024-06-24 | Forty Seven Inc | Terapias combinadas para el tratamiento de síndromes mielodisplásicos y leucemia mieloide aguda |
| JP2022552748A (ja) | 2019-10-31 | 2022-12-19 | フォーティ セブン， インコーポレイテッド | 抗ｃｄ４７及び抗ｃｄ２０による血液癌の治療 |
| US12195723B2 (en) * | 2019-11-08 | 2025-01-14 | The Broad Institute, Inc. | Engineered antigen presenting cells and uses thereof |
| CN115925976A (zh) * | 2019-11-21 | 2023-04-07 | 博生吉医药科技(苏州)有限公司 | Cd7-car-t细胞及其制备和应用 |
| CA3163258A1 (en) * | 2019-11-27 | 2021-06-03 | Board Of Regents, The University Of Texas System | Large-scale combined car transduction and crispr gene editing of nk cells |
| US20230045174A1 (en) * | 2019-11-27 | 2023-02-09 | Board Of Regents, The University Of Texas System | Large-scale combined car transduction and crispr gene editing of msc cells |
| IL294032A (en) | 2019-12-24 | 2022-08-01 | Carna Biosciences Inc | Compounds that regulate diacylglycerol kinase |
| CA3166832A1 (en) * | 2020-01-08 | 2021-07-15 | Board Of Regents, The University Of Texas Systems | A method of engineering natural killer cells to target cd70-positive tumors |
| WO2021202581A1 (en) * | 2020-03-30 | 2021-10-07 | WUGEN, Inc. | Engineered immune cells for adoptive cell therapy |
| CN113913458A (zh) * | 2020-07-09 | 2022-01-11 | 杭州优凯瑞医药科技有限公司 | 非病毒方法制备稳定高表达嵌合受体的nk细胞 |
| US11459372B2 (en) | 2020-11-30 | 2022-10-04 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| EP4255453A4 (en) * | 2020-12-03 | 2025-03-26 | Nkarta, Inc. | Methods for manipulating immune cells for increased potency and persistence, as well as uses of engineered cells in immunotherapy |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| KR20230118887A (ko) | 2020-12-03 | 2023-08-14 | 센츄리 쎄라퓨틱스 인코포레이티드 | 유전자 조작 세포 및 이의 용도 |
| WO2022129216A1 (en) | 2020-12-15 | 2022-06-23 | Universiteit Antwerpen | Cell-based therapeutics targeting cd70 |
| AR124414A1 (es) | 2020-12-18 | 2023-03-22 | Century Therapeutics Inc | Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable |
| WO2022144632A1 (en) | 2020-12-30 | 2022-07-07 | Crispr Therapeutics Ag | Compositions and methods for differentiating stem cells into nk cells |
| TW202245598A (zh) | 2021-02-09 | 2022-12-01 | 美商千禧製藥公司 | 用於冷凍及解凍哺乳動物細胞的方法及組成物 |
| CN113005151A (zh) * | 2021-03-12 | 2021-06-22 | 广东药科大学 | 一种kdr-car-nk细胞的制备方法及其应用 |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| MX2023011712A (es) | 2021-04-26 | 2023-10-12 | Millennium Pharm Inc | Anticuerpos anti receptor de adhesion acoplado a proteinas g e2 (adgre2) y usos de los mismos. |
| CN117355600A (zh) * | 2021-05-20 | 2024-01-05 | 上海药明生物技术有限公司 | 遗传修饰的nk细胞及其用途 |
| JP7686091B2 (ja) | 2021-06-23 | 2025-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| AU2022299051B2 (en) | 2021-06-23 | 2025-03-13 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| MX2023014762A (es) | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| JP7651018B2 (ja) | 2021-06-23 | 2025-03-25 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| CN113599395B (zh) * | 2021-09-22 | 2022-08-12 | 郑州源创吉因实业有限公司 | 含有nk细胞的治疗癌症的药物组合物 |
| IL311665A (en) * | 2021-10-01 | 2024-05-01 | Univ Texas | Antibody loaded immune cells and methods for use in cancer treatment |
| WO2023062113A1 (en) * | 2021-10-15 | 2023-04-20 | Miltenyi Biotec B.V. & Co. KG | Method for the generation of genetically modified nk cells |
| JP2024539129A (ja) * | 2021-10-21 | 2024-10-28 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増強された代謝適合性を有する治療用免疫細胞の製造方法およびその組成物 |
| AU2022381757A1 (en) * | 2021-11-04 | 2024-05-09 | Saliogen Therapeutics, Inc. | Immune cells with chimeric antigen receptors or chimeric autoantibody receptors |
| TW202338085A (zh) | 2021-11-18 | 2023-10-01 | 美商健生生物科技公司 | 用於擴增自然殺手細胞製劑之無餵養細胞培養方法 |
| KR20240165995A (ko) | 2022-03-24 | 2024-11-25 | 길리애드 사이언시즈, 인코포레이티드 | Trop-2 발현 암의 치료를 위한 병용요법 |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| CN114774364B (zh) * | 2022-04-26 | 2024-04-26 | 深圳市体内生物医药科技有限公司 | 一种嵌合抗原受体t细胞及其制备方法和应用 |
| WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
| CN120152735A (zh) * | 2022-10-25 | 2025-06-13 | 武田药品工业株式会社 | Adgre2嵌合受体nk细胞组合物和使用方法 |
| JP2025536042A (ja) * | 2022-11-10 | 2025-10-30 | オーエヌケイ セラピューティクス リミテッド | 免疫調節薬を用いた併用療法 |
| CN115947869B (zh) * | 2022-11-28 | 2023-12-12 | 广州佰芮慷生物科技有限公司 | 一种靶向人巨细胞病毒的嵌合抗原受体、car-nk细胞及用途 |
| CN116731972A (zh) * | 2023-02-10 | 2023-09-12 | 上海交通大学 | 嵌合抗原受体t细胞、制备方法及其用途 |
| CN115948344A (zh) * | 2023-02-10 | 2023-04-11 | 上海交通大学 | 嵌合抗原受体nk细胞、制备方法及其用途 |
| KR20250166262A (ko) * | 2023-03-24 | 2025-11-27 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 향상된 항종양 기억 반응을 갖는 조작된 자연 살해 세포 |
| EP4687965A1 (en) * | 2023-04-07 | 2026-02-11 | Nkarta, Inc. | Methods for treatment of autoimmune diseases |
| CN116769722B (zh) * | 2023-07-04 | 2024-07-16 | 杭州荣谷生物科技有限公司 | 功能增强型car-nk细胞、其制备方法及其在免疫疗法中的应用 |
| WO2025059162A1 (en) | 2023-09-11 | 2025-03-20 | Dana-Farber Cancer Institute, Inc. | Car-engager containing il-2 variants to enhance the functionality of car t cells |
| WO2025073908A1 (en) * | 2023-10-05 | 2025-04-10 | Onk Therapeutics Limited | Optimised il-15 constructs |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012136231A1 (en) * | 2010-09-08 | 2012-10-11 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Interleukin 15 as selectable marker for gene transfer in lymphocytes |
| EP3326467B1 (en) * | 2011-09-16 | 2020-03-11 | Baylor College of Medicine | Targeting the tumor microenvironment using manipulated nkt cells |
| ES2652666T3 (es) * | 2011-12-22 | 2018-02-05 | Mogam Biotechnology Institute | Procedimiento de producción de linfocitos citolíticos naturales, linfocitos citolíticos naturales producidos de este modo y composición para el tratamiento de cánceres y enfermedades infecciosas que contienen los mismos |
| GB2592821B (en) * | 2015-07-31 | 2022-01-12 | Univ Minnesota | Modified cells and methods of therapy |
| EP3827838B1 (en) * | 2015-12-16 | 2023-06-07 | The Walter and Eliza Hall Institute of Medical Research | Inhibition of cytokine-induced sh2 protein in nk cells |
| MX2018008345A (es) * | 2016-01-11 | 2018-12-06 | Univ Leland Stanford Junior | Proteínas quiméricas y métodos de inmunoterapia. |
| EP3402495A4 (en) * | 2016-01-15 | 2019-06-19 | Etubics Corporation | METHOD AND COMPOSITIONS FOR T-CELL IMMUNOTHERAPY |
| CN109890408A (zh) * | 2016-05-27 | 2019-06-14 | 埃特彼塞斯公司 | 新表位疫苗组合物及其使用方法 |
| AU2017347854B2 (en) * | 2016-10-27 | 2022-12-08 | Intima Bioscience, Inc. | Viral methods of T cell therapy |
| EP3612210A4 (en) * | 2017-04-19 | 2021-01-27 | Board Of Regents, The University Of Texas System | MANIPULATED ANTIGEN RECEPTORS EXPRESSING IMMUNE CELLS |
| MX2021011816A (es) * | 2019-03-29 | 2021-10-22 | Univ Texas | Metodos para produccion de celulas car-nk y uso de las mismas. |
-
2019
- 2019-05-03 KR KR1020207034764A patent/KR20210005240A/ko not_active Ceased
- 2019-05-03 BR BR112020022010-8A patent/BR112020022010A2/pt unknown
- 2019-05-03 CN CN201980037453.2A patent/CN112292390A/zh active Pending
- 2019-05-03 SG SG11202010763VA patent/SG11202010763VA/en unknown
- 2019-05-03 EP EP19795874.7A patent/EP3788061A4/en active Pending
- 2019-05-03 JP JP2020561821A patent/JP2021522798A/ja not_active Ceased
- 2019-05-03 MX MX2020011697A patent/MX2020011697A/es unknown
- 2019-05-03 AU AU2019262218A patent/AU2019262218B2/en active Active
- 2019-05-03 CA CA3099342A patent/CA3099342A1/en active Pending
- 2019-05-03 NZ NZ770183A patent/NZ770183A/en unknown
- 2019-05-03 WO PCT/US2019/030721 patent/WO2019213610A1/en not_active Ceased
- 2019-05-03 US US17/050,775 patent/US20210230548A1/en active Pending
-
2020
- 2020-12-02 CO CONC2020/0015168A patent/CO2020015168A2/es unknown
-
2024
- 2024-01-05 JP JP2024000389A patent/JP2024045179A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021522798A5 (enExample) | ||
| CN113286811B (zh) | 改善过继性细胞疗法的效力和安全性 | |
| Liu et al. | NK cell-based cancer immunotherapy: from basic biology to clinical development | |
| Ames et al. | Advantages and clinical applications of natural killer cells in cancer immunotherapy | |
| Thomson et al. | Double-negative regulatory T cells: non-conventional regulators | |
| CN108025024B (zh) | 表达嵌合抗原受体的修饰单核细胞/巨噬细胞及其用途 | |
| US20240325450A1 (en) | Nkt-cell subset for in vivo persistence and therapeutic activity and propagation of same | |
| JP6899333B2 (ja) | 汎用キラーｔ細胞 | |
| EP1434596B1 (en) | Enhancement of immune responses by agonist 4-1bb-antibodies | |
| JP2022512968A5 (enExample) | ||
| JP2016539929A5 (enExample) | ||
| JP2021501604A5 (enExample) | ||
| US20210113691A1 (en) | Use of Triplex CMV Vaccine in CAR T Cell Therapy | |
| Hu et al. | Natural killer cell-based immunotherapy for cancer: advances and prospects | |
| EP3474888A1 (en) | Adoptive cell transfer and oncolytic virus combination therapy | |
| CN115768879A (zh) | 用于培养细胞的方法 | |
| CN110404061B (zh) | 改进的t细胞治疗方法 | |
| JP2024509095A5 (enExample) | ||
| TWI800522B (zh) | 醫藥重組受體組成物及方法 | |
| JP2023521037A5 (enExample) | ||
| KR20230150833A (ko) | 세포 배양 방법 | |
| US20230030680A1 (en) | Chimeric gmcsf-il18 receptor | |
| Letessier et al. | Enrichment in tumor-reactive CD8+ T-lymphocytes by positive selection from the blood and lymph nodes of patients with head and neck cancer | |
| CN117203328A (zh) | 重组抗原呈递细胞 | |
| Yee | Adoptive therapy using antigen-specific T-cell clones |